Advancing a pipeline of therapeutics built from our platform. Schrödinger’s therapeutics group strives to reduce risk in drug discovery and development by selecting high-value targets with established human genetics or clinical validation, where we can solve a design challenge, and where we believe we can deliver value for patients.

Complete modeling environment for your molecular discovery. Discover better quality molecules, faster. Maestro is Schrödinger’s streamlined portal for access to state-of-the-art predictive computational modeling and machine learning workflows for molecular discovery.

シュレーディンガーは、製薬、バイオテクノロジー、材料研究で使用される最先端の化学シミュレーション ソフトウェアの開発における科学的リーダーです。

Explore how Schrödinger solutions can solve research challenges across materials science application areas

Proprietary Pipeline Highlights. SGR-1505 (MALT1) SGR-1505 is a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor. SGR-2921 (CDC7) SGR-2921 is a cell division cycle 7-related protein kinase (CDC7) inhibitor. SGR-3515 (Wee1/Myt1) SGR-3515 is a Wee1/Myt1 inhibitor.

We are driven to be the world leader in transforming drug discovery and materials design by relentlessly pursuing scientific and technology breakthroughs.; We are committed to achieving the best possible outcomes for our customers, partners, patients, and other stakeholders.; We deeply value our dedicated employees and invest in their growth, development, and well-being.

SGR-3515 is a Wee1 G2 Checkpoint Kinase and Membrane Associated Tyrosine/Threonine 1 (Wee1/Myt1) inhibitor. Wee1 is a gatekeeper checkpoint kinase that prevents cellular progression through the cell cycle, allowing time for DNA repair before cell division takes place.

Our physics-based computational platform integrates differentiated solutions for predictive modeling, data analytics, and collaboration to enable rapid exploration of chemical space.

Proprietary Pipeline Highlights. SGR-1505 (MALT1) SGR-1505 is a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor. SGR-2921 (CDC7) SGR-2921 is a cell division cycle 7-related protein kinase (CDC7) inhibitor. SGR-3515 (Wee1/Myt1) SGR-3515 is a Wee1/Myt1 inhibitor.

Founded in 1990, Schrödinger has approximately 850 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com. Cautionary Note Regarding Forward-Looking Statements